Navigation Links
Possible AIDS Treatment Shows Promise in Monkeys
Date:12/10/2008

It stops virus from fooling immune cells, researchers say

WEDNESDAY, Dec. 10 (HealthDay News) -- Researchers report that a treatment under development appears to stop the equivalent of the AIDS virus in monkeys.

Nine rhesus macaque monkeys infected with a virus known as SIV underwent treatment and remain alive eight months later. The treatment appears to work by preventing virus cells from fooling the immune system.

There's no guarantee that the treatment will work in people. But if it's effective in humans, the treatment could allow patients to avoid taking AIDS drugs for the rest of their lives, said study co-author Rama Rao Amara, an assistant professor at Emory University's Yerkes National Primate Research Center.

"If you wake up and realize you don't have to take a pill, it's a big step forward," he said. In addition, he said, current AIDS drugs are expensive and have serious side effects.

Existing AIDS drugs do have benefits: They're often effective and have allowed patients to live normal lives. However, they can't always keep up with the AIDS virus, which evolves quickly and can become immune to current treatments.

"The virus changes and then these drugs don't work after some time," Amara said.

In the new study, Amara and colleagues injected nine monkeys with an antibody that blocks a kind of "don't kill me" signal that cells infected with simian immunodeficiency virus (SIV) send to immune cells.

When the SIV-infected cells emit the signal, "the killer cell thinks, 'You are not my enemy. You're my friend,'" Amara said. But when the signal is blocked, the killer immune cells can do their job and wipe out the virus.

The researchers gave four injections of the antibody to the monkeys over 10 days and then watched to see what happened.

The study appears in the Dec. 10 online edition of Nature

The monkeys, infected with SIV for as long as 21 months, were able to beat back the virus. Levels of virus in the blood dropped and the animals remained alive.

By contrast, four out of five monkeys who received a "control" antibody died within four months.

"What is amazing to me how rapidly you can actually change these killer cells," Amara said. "Now they are good cells."

The work of the monkeys is done and they will be euthanized, Amara said. It is too expensive -- $7 a day each -- to pay for their care with available funding, he said.

In humans, the treatment could cost a couple thousand dollars per dose, Amara said, although patients might then avoid taking drugs for life.

Dr. Mark Connors, a specialist in AIDS research, said the research is "clearly valid and very interesting. I'm sure it's going to generate debate over the next year or so as to what it means."

Even skeptics may be convinced by evidence that the treatment directly affects survival and the level of the virus in the body, said Connors, chief of the HIV-Specific Immunity Section at the U.S. National Institute of Allergy & Infectious Diseases.

As for the future, Connors said he's "guardedly optimistic" that the treatment could be used in humans, perhaps in conjunction with other medications.

More information

To learn more about AIDS, go to AIDS.gov.



SOURCES: Rama Rao Amara, Ph.D., assistant professor, Yerkes National Primate Research Center, Emory University, Atlanta; Mark Connors, M.D., chief, HIV-Specific Immunity Section, U.S. National Institute of Allergy & Infectious Diseases, Bethesda, Md.; Dec. 10, 2008, Nature, online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Condell Health Network and Medical Center to Pay $36 Million Settlement After Self-Reporting Possible Health-Care Fraud
2. Great California Workplace Award Goes to Company Facing Lawsuits, Possible Federal Complaint
3. Finding Points to Possible Blood Test for Brain Tumors
4. Revolutionary Procedure for the Treatment of Gastroesophageal Reflux Now Possible in San Francisco Thanks to Dr. Paul Cirangle
5. Possible link between diabetes and pelvic girdle syndrome
6. Possible association between CP and LC of alcoholic etiology
7. Researchers identify mechanism, possible drug treatment for tumors in neurofibromatosis
8. Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible
9. LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis
10. Later Use of Clot-Buster After Stroke Possible: Study
11. Study: Delaying evolution of drug resistance in malaria parasite possible
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Possible AIDS Treatment Shows Promise in Monkeys
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology: